From a median baseline fasting TG of 262 mg/dL (2.96 mmol/L), AKCEA-APOCIII-LRx 50 mg Q4W reduced TG compared to placebo by -62% at 6 months, p<0.0001, with 91% achieving TG <150 mg/dL.
Please login or create a FREE account to view this content
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.